Network pharmacology analysis indicated that FCGs may ameliorate MASLD through multi-target mechanisms, including modulation of insulin resistance, lipid metabolism, inflammation, and apoptosis. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.